Skip to main content
Terug
Watch Compare

NovaBridge Biosciences

Datakwaliteit: 83%
NBP
NASDAQ Manufacturing Chemicals
€ 2,60
▲ € 0,06 (2,36%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-53,75%

Groei

Revenue Growth (5Y)
-53,75%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-20,31%
Boven sectorgemiddelde (-54,47%)
ROIC-32,33%
Net Margin-7321,04%
Op. Margin-14915,98%

Veiligheid

Debt / Equity
N/A
Current Ratio14,47
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-6,01 | -2,23
Onder sectorgemiddelde (-1,49)
P/B Ratio1,07
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -53,75% annually over 5 years
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 53,75%
Capital efficient — spends only 1,11% of revenue on capex

Price History

Financiële Trends

Koersdoel Analisten

4 analisten
Buy
+217.3%
upside to target
Huidig
€ 2,60
Consensus Target
€ 8,25
€ 7,00
Laag
€ 9,00
Hoog
Vooruitzicht
Forward K/W
-2,23
Forward WPA
-€ 1,06
Omzet Sch.
0,0

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,23 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,04 -€ 0,07 -€ 0,06 -€ 0,31 — —
Estimate -€ 0,07 -€ 0,12 -€ 0,05 -€ 0,08 -€ 0,23 -€ 0,24
Verrassing +42,86% +41,67% -20,00% -287,50% — —

Growth

Rev 5Y: -53,75% · Earnings 1Y: N/A
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) -59,71%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -53,75% Earnings Growth (5Y) N/A

Profitability

ROE: -20,31% · Net Margin: -7321,04%
Revenue (TTM) 632.000,0 Net Income (TTM) -46,27 M
ROE -20,31% ROA -19,11%
Gross Margin N/A Operating Margin -14915,98%
Net Margin -7321,04% Free Cash Flow (TTM) N/A
ROIC -32,33% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 14,47
Debt / Equity N/A Current Ratio 14,47
Interest Coverage N/A Asset Turnover 0,00
Working Capital 216,68 M Tangible Book Value 258,92 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -6,01 · EV/EBITDA: N/A
P/E Ratio -6,01 Forward P/E -2,23
P/B Ratio 1,07 P/S Ratio 439,64
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield N/A
Market Cap 277,85 M Enterprise Value 49,79 M

Per Share

EPS: -0,21 · FCF/Share: N/A
EPS (Diluted TTM) -0,21 Revenue / Share 0,01
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: N/A · CapEx/Rev: 1,11%
CapEx / Revenue 1,11% FCF Conversion N/A
SBC-Adj. FCF N/A Growth Momentum 53,75

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 632.000,0 632.000,0 3,89 M -32,12 M 13,81 M
Net Income -46,27 M -22,23 M -206,44 M -363,53 M -365,87 M
EPS (Diluted) -0,21 -0,12 -1,08 -1,92 -2,09
Gross Profit — — — — —
Operating Income -94,27 M -51,43 M — — —
EBITDA — — — — —
R&D Expenses 62,91 M 21,77 M 114,18 M 131,20 M 190,34 M
SG&A Expenses — — — — —
D&A — 300.000,0 3,40 M 3,70 M —
Interest Expense — — 102.000,0 1.000,0 0,0
Income Tax 0,0 0,0 — 101.000,0 -495.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 260,52 M 212,68 M 368,03 M 590,63 M 878,95 M
Total Liabilities 29,58 M 11,52 M 126,03 M 168,73 M 163,45 M
Shareholders' Equity 230,94 M 201,16 M 242,00 M 421,90 M 715,50 M
Total Debt — — 4,22 M 2,75 M —
Cash & Equivalents 210,63 M 68,26 M 301,62 M 465,99 M 552,94 M
Current Assets 217,52 M 176,69 M 329,11 M 525,79 M 750,36 M
Current Liabilities 26,89 M 8,45 M 58,00 M 109,92 M 97,92 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -6,0 -1,5
P/B 1,1 1,6
ROE % -20,3 -54,5
Net Margin % -7321,0 -41,5
Rev Growth 5Y % -53,8 1,8
D/E — 0,3